John Karanicolas, PhD, Joins the Fox Chase Cancer Center Molecular Therapeutics Program

PHILADELPHIA (August 12, 2016) – John Karanicolas, PhD, has joined Fox Chase Cancer Center as an associate professor in the Molecular Therapeutics Program.

Karanicolas, a computational chemist, earned his PhD from the Scripps Research Institute. He completed his postdoctoral fellowship at the University of Washington. He comes to Fox Chase from the University of Kansas, where he served as an associate professor in the Department of Molecular Biosciences and Center for Computational Biology.

“Dr. Karanicolas is an accomplished and renowned scientist,” said Wafik El-Deiry, MD, PhD, coleader of the Molecular Therapeutics Program at Fox Chase. “His knowledge and experience in the field of chemical biology make him an important addition to both the scientific community here at Fox Chase and our Molecular Therapeutics Program.”

Karanicolas will have his own lab at the Center. His start date at Fox Chase is August 18.

“Fox Chase Cancer Center is continuously recognized as one of the best cancer centers in the country,” said Karanicolas. “I am looking forward to working with world-class clinicians and scientists as we strive to end cancer as we know it.”

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text